Experienced in Primary Immunodeficiency (PID)

Dr. Dipti Patel

Hematology | Oncology
8613 Route 29, 200n, 
Fairfax, VA 
Offers Telehealth
Experienced in Primary Immunodeficiency (PID)
8613 Route 29, 200n, 
Fairfax, VA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dipti Patel is a Hematologist and an Oncologist in Fairfax, Virginia. Dr. Patel is rated as an Experienced provider by MediFind in the treatment of Primary Immunodeficiency (PID). Her top areas of expertise are Multiple Myeloma, Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), Bone Marrow Aspiration, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 10 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in VA
Hospital Affiliations
Inova Fairfax Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Innovation Health
  • HMO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PacificSource
  • PPO
Piedmont
  • HMO
  • POS
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

VIRGINIA CANCER SPECIALISTS, P.C.
8613 Route 29, 200n, Fairfax, VA 22031
Other Locations
VIRGINIA CANCER SPECIALISTS, P.C.
9450 Innovation Dr, Manassas, VA 20110

Additional Areas of Focus

Dr. Patel has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (Apilimod Dimesylate Capsules) Administered Orally in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (Apilimod Dimesylate Capsules) Administered Orally in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Enrollment Status: Completed
Publish Date: August 22, 2024
Intervention Type: Drug
Study Drugs: Apilimod, Rituximab, Atezolizumab
Study Phase: Phase 1
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
Enrollment Status: Completed
Publish Date: June 11, 2024
Intervention Type: Drug
Study Drugs: Brentuximab, Bendamustine, Dacarbazine, Nivolumab
Study Phase: Phase 2
A Phase 1/2, Open-Label, Uncontrolled, Multiple Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Relapsed/Refractory Lymphoma, Myelofibrosis, Chronic Lymphocytic Leukemia, And Advanced Solid Tumors
A Phase 1/2, Open-Label, Uncontrolled, Multiple Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Relapsed/Refractory Lymphoma, Myelofibrosis, Chronic Lymphocytic Leukemia, And Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: June 07, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
Enrollment Status: Terminated
Publish Date: November 19, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Study of Brentuximab Vedotin in Combination With Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) as Front-line Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
A Phase 2 Study of Brentuximab Vedotin in Combination With Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) as Front-line Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Terminated
Publish Date: June 21, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

10 Total Publications

Acute leukemias and complicated lymphomas: pearls to optimize management when patients stay local.
Acute leukemias and complicated lymphomas: pearls to optimize management when patients stay local.
Journal: Hematology. American Society of Hematology. Education Program
Published: December 09, 2023
Similar Doctors
Advanced in Primary Immunodeficiency (PID)
Dr. Jennifer A. Kanakry
Hematology | Oncology
Advanced in Primary Immunodeficiency (PID)
Dr. Jennifer A. Kanakry
Hematology | Oncology

Regional Cancer Care Associates LLC

3800 Reservoir Rd Nw, 
Washington, DC 
 (10.6 miles away)
202-444-3736
Languages Spoken:
English
See accepted insurances

Jennifer Kanakry is a Hematologist and an Oncologist in Washington, Washington, D.c.. Dr. Kanakry is rated as an Advanced provider by MediFind in the treatment of Primary Immunodeficiency (PID). Her top areas of expertise are Graft Versus Host Disease (GvHD), Primary Immunodeficiency (PID), Hodgkin Lymphoma, Classical Hodgkin Lymphoma, and Bone Marrow Transplant.

Advanced in Primary Immunodeficiency (PID)
Dr. Amr Z. Hegazi
Hematology Oncology | Hematology | Oncology
Advanced in Primary Immunodeficiency (PID)
Dr. Amr Z. Hegazi
Hematology Oncology | Hematology | Oncology

Maryland Oncology Hematology PA

11886 Healing Way, 
Silver Spring, MD 
 (20.9 miles away)
301-933-3216
Languages Spoken:
English, Arabic, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Amr Hegazi is a Hematologist Oncology specialist and a Hematologist in Silver Spring, Maryland. Dr. Hegazi is rated as a Distinguished provider by MediFind in the treatment of Primary Immunodeficiency (PID). His top areas of expertise are Iron Deficiency Anemia, Childhood Iron Deficiency Anemia, Anemia, Pulmonary Embolism, and Bone Marrow Aspiration. Dr. Hegazi is currently accepting new patients.

Experienced in Primary Immunodeficiency (PID)
Dr. Elhamy D. Eskander
Oncology | Hematology | Hematology Oncology
Experienced in Primary Immunodeficiency (PID)
Dr. Elhamy D. Eskander
Oncology | Hematology | Hematology Oncology

Frederick Health Medical Group LLC

194 Thomas Johnson Dr, 
Frederick, MD 
 (41.4 miles away)
240-215-6310
Languages Spoken:
English
See accepted insurances

Elhamy Eskander is an Oncologist and a Hematologist in Frederick, Maryland. Dr. Eskander is rated as a Distinguished provider by MediFind in the treatment of Primary Immunodeficiency (PID). His top areas of expertise are Lung Cancer, Childhood Iron Deficiency Anemia, Pleuropulmonary Blastoma, and Autoimmune Hemolytic Anemia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Patel's expertise for a condition
ConditionClose
    View All 15 Distinguished Conditions
    View All 64 Advanced Conditions
    View All 90 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile